0001231919-26-000695.txt : 20260624 0001231919-26-000695.hdr.sgml : 20260624 20260624171837 ACCESSION NUMBER: 0001231919-26-000695 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: Rule 506(b) provides a "safer harbor" for a private offering FILED AS OF DATE: 20260624 DATE AS OF CHANGE: 20260624 EFFECTIVENESS DATE: 20260624 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Dravite Therapeutics, Inc. CENTRAL INDEX KEY: 0002133272 ORGANIZATION NAME: EIN: 394859793 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-588496 FILM NUMBER: 261116870 BUSINESS ADDRESS: STREET 1: 401 CAMBRIDGE STREET CITY: SAN FRANCISCO STATE: CA ZIP: 94134 BUSINESS PHONE: 650-269-3210 MAIL ADDRESS: STREET 1: 401 CAMBRIDGE STREET CITY: SAN FRANCISCO STATE: CA ZIP: 94134 D 1 primary_doc.xml X0708 D LIVE 0002133272 Dravite Therapeutics, Inc. 401 CAMBRIDGE STREET SAN FRANCISCO CA CALIFORNIA 94134 650-269-3210 DELAWARE None None Corporation true 2025 JOSEPH SUM C/O DRAVITE THERAPEUTICS, INC. 401 CAMBRIDGE ST SAN FRANCISCO CA CALIFORNIA 94134 Director SANDEEP KULKARNI C/O DRAVITE THERAPEUTICS, INC. 401 CAMBRIDGE ST SAN FRANCISCO CA CALIFORNIA 94134 Director BARBARA KOSACZ C/O DRAVITE THERAPEUTICS, INC. 401 CAMBRIDGE ST SAN FRANCISCO CA CALIFORNIA 94134 Director MICHAEL MOORE C/O DRAVITE THERAPEUTICS, INC. 401 CAMBRIDGE ST SAN FRANCISCO CA CALIFORNIA 94134 Executive Officer Director Other Decline to Disclose 06b false 2026-04-20 false true false 0 14983333 14983333 0 false 8 0 0 0 false Dravite Therapeutics, Inc. /s/ Michael Moore Michael Moore CEO 2026-06-24